Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) shares crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $0.00 and traded as high as $0.89. Ampio Pharmaceuticals shares last traded at $0.88, with a volume of 3,504,478 shares.

Separately, Zacks Investment Research lowered shares of Ampio Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, June 9th.

Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) last announced its quarterly earnings results on Friday, July 31st. The specialty pharmaceutical company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.02.

A number of hedge funds have recently made changes to their positions in the stock. Miracle Mile Advisors LLC increased its holdings in Ampio Pharmaceuticals by 100.0% during the 2nd quarter. Miracle Mile Advisors LLC now owns 40,000 shares of the specialty pharmaceutical company’s stock valued at $25,000 after purchasing an additional 20,000 shares in the last quarter. Chicago Partners Investment Group LLC grew its holdings in shares of Ampio Pharmaceuticals by 19.4% during the second quarter. Chicago Partners Investment Group LLC now owns 61,523 shares of the specialty pharmaceutical company’s stock worth $72,000 after purchasing an additional 10,000 shares during the last quarter. Advisor Group Holdings Inc. acquired a new stake in shares of Ampio Pharmaceuticals in the first quarter valued at $42,000. Bank of Montreal Can bought a new position in shares of Ampio Pharmaceuticals in the second quarter valued at about $248,000. Finally, Bridgeway Capital Management Inc. acquired a new position in Ampio Pharmaceuticals during the 2nd quarter worth about $746,000.

Ampio Pharmaceuticals Company Profile (NYSEAMERICAN:AMPE)

Ampio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds. Its product pipeline includes Ampion, an intra-articular injection for the treatment of osteoarthritis of the knee.

Recommended Story: How Short Selling Works

Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.